8-K: Catheter Precision Reports Soaring Q2 Revenue, CE Mark

Catheter Precision, Inc. announced a 128% year-over-year revenue increase in Q2 2025, alongside key product advancements and clinical data, despite continued net losses and liquidity concerns.

Summary

• Revenue for the second quarter ended June 30, 2025, increased 128% to approximately $212 thousand, up from $93 thousand in Q2 2024.
• First half 2025 revenue grew 103% to approximately $355 thousand, compared to $175 thousand in the first half of 2024.
• Sequential quarter-over-quarter sales increased 48%.
• The CE Mark for the LockeT product was received during the quarter, with European sales anticipated to commence in Q3 2025.
• Significant clinical data for VIVO and LockeT was presented at the annual Heart Rhythm Society symposium, demonstrating VIVO's over 94% accuracy and potential to improve long-term outcomes (over 83% procedural success), and LockeT's safety and efficacy in large-bore access procedures.
• The acquisition of Cardionomics heart failure assets was completed by the newly formed 82%-owned subsidiary, Cardionomix.
• Kardionav, Inc., a majority-owned joint venture, was formed to develop an implant-based software product for precise ablation site location for ventricular tachyarrhythmia.
• Net loss for Q2 2025 was approximately $5.4 million, including $3.2 million in non-cash charges.
• Net loss for the first six months of 2025 was approximately $9.5 million, including $4.4 million in non-cash charges.
• Total assets were $25.6 million and total shareholders' equity was $6.5 million as of June 30, 2025.
• Cash position as of June 30, 2025, was $838 thousand.

Sentiment

Score: 5

Explanation: While the company shows strong revenue growth and significant product development milestones (CE Mark, clinical data, new ventures), the substantial net losses, critically low cash position, and disclosed ineffective internal controls present significant financial and operational risks. The positive operational momentum is heavily offset by the urgent need for capital and governance issues.

Positives

• Revenue increased 128% year-over-year in Q2 2025 and 103% in the first half of 2025, indicating strong sales growth.
• Sequential quarter-over-quarter sales increased by a robust 48%.
• Received CE Mark for the LockeT product, opening the European market for sales expected to begin in Q3 2025.
• Presented significant positive clinical data for VIVO and LockeT at a major industry symposium, validating product efficacy and accuracy.
• Completed the acquisition of Cardionomics heart failure assets, expanding the company's product pipeline and market reach.
• Formed Kardionav, Inc. joint venture to develop an innovative implant-based software for ventricular tachyarrhythmia, addressing a critical unmet medical need.

Negatives

• Reported a net loss of approximately $5.4 million for Q2 2025 and $9.5 million for the first half of 2025.
• Cash position was low at $838 thousand as of June 30, 2025.
• Insufficient liquidity to fund operations through December 31, 2025, without additional financing or a strategic transaction.
• Internal controls and disclosure controls were determined to be ineffective as of June 30, 2025, March 31, 2025, and December 31, 2024, posing risks to financial reporting accuracy and fraud prevention.

Risks

• Further and larger studies are needed to confirm the results presented at the annual Heart Rhythm Society symposium.
• Unable to develop assets acquired by KardioNav and Cardionomix without obtaining additional financing, which may not be available on acceptable terms or at all.
• Anticipated trials may not turn out as expected, or future trials may not occur on expected timetables or may be more costly than anticipated.
• Insufficient liquidity to fund operations through December 31, 2025, without additional financing or a strategic transaction.
• Will not be able to reach profitability unless product expansion and growth goals are achieved.
• Research and development and commercialization efforts may depend on entering into agreements with corporate collaborators.
• Joint marketing agreements may reduce revenues from product sales.
• Royalty agreements for the LockeT device will reduce any future profits from this product.
• Significant disruptions in information technology systems could adversely affect the business.
• Litigation and other legal proceedings may adversely affect the business.
• Difficulties encountered during acquisitions or divestitures could harm the business.
• Failure to attract and retain sufficient qualified personnel could impede growth.
• Failure to maintain effective internal controls could cause investors to lose confidence and adversely affect the common stock price.
• Revenues may depend on customers' receipt of adequate reimbursement from private insurers and government-sponsored healthcare programs.
• Inability to compete successfully with companies in a highly competitive industry, many of whom have substantially greater resources.
• Future operating results depend upon the ability to obtain components in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality, and volumes.
• Suppliers may fail to deliver components, or the company may be unable to manage or obtain these components effectively.
• Inability to generate significant revenue if hospitals, physicians, and patients do not accept current and future products or if the market for indications is smaller than expected.
• Medical device operations are subject to pervasive and continuing FDA regulatory requirements.
• Products may be subject to additional recalls, revocations, or suspensions after receiving FDA or foreign approval or clearance.
• Changes in trade policies among the U.S. and other countries, including new or higher tariffs, could place pressure on average selling prices and have a material adverse effect on revenues and operating results.
• Risks may be amplified by the COVID-19 pandemic, other pandemics, supply chain disruptions from geopolitical conflicts (Ukraine war, Israeli-Hamas conflict), and ongoing volatility in stock markets and the U.S. economy.

Future Outlook

The company anticipates LockeT sales to commence in Europe during the third quarter of 2025. Management expects continued increased awareness and desire for its products in both the US and international markets, aiming to increase the future value of Catheter Precision. The team is energized and looking forward to results in the coming quarters.

Management Comments

• "We are extremely excited about our results on all fronts: increasing sales, strong clinical data, and execution of strategic transactions with a goal of increasing the future value of Catheter Precision."
• "We are seeing increased awareness and desire for our products, both here in the US, and now, with the CE Mark for the LockeT in Europe, internationally as well."
• "The team is energized with our progress, and we are looking forward to our results in the coming quarters."

Industry Context

Catheter Precision operates in the cardiac electrophysiology market, a specialized segment of the medical device industry focused on diagnosing and treating heart rhythm disorders. The company's products, VIVO and LockeT, address critical needs in this field by improving pre-procedural planning, procedural efficiency, and post-procedure hemostasis. The acquisition of heart failure assets and the formation of a joint venture for ventricular tachyarrhythmia treatment indicate a strategic expansion into related, high-growth areas within cardiology, aligning with broader industry trends towards less invasive procedures and advanced imaging/mapping technologies.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks. However, the clinical data presented for VIVO (over 94% accuracy, over 83% long-term procedural success) and LockeT (safe and effective hemostasis in 139 patients) suggests positive performance for their respective applications within the cardiac electrophysiology device market.
• The company's revenue growth of 128% year-over-year is significant for a medical device company, especially for a smaller player, and would generally be considered strong compared to many established industry players, though specific market share or competitive positioning data is not provided.

Corporate Governance

Legal Proceedings

• The company notes that litigation and other legal proceedings may adversely affect its business, but no specific current proceedings are detailed in the filing.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution if a capital raise occurs, but also potential for long-term value creation if product development and sales growth continue and financial stability is achieved. Current ineffective internal controls pose a risk to investor confidence.
• **Employees**: Continued growth and product development could lead to job security and expansion, but financial instability and the need for additional financing could create uncertainty.
• **Customers (Hospitals, Physicians, Patients)**: Benefit from new and effective medical devices (VIVO, LockeT) that improve cardiac electrophysiology procedures. Product availability and support depend on the company's financial health.
• **Suppliers**: Continued demand for components, but potential risk if the company's liquidity issues affect its ability to pay for supplies.
• **Creditors**: High risk due to the company's low cash position and stated insufficient liquidity, indicating potential challenges in meeting short-term obligations without new financing.

Next Steps

• Begin sales of the LockeT product in Europe during the third quarter of 2025.
• Continue development of the implant-based software product for ventricular tachyarrhythmia through the Kardionav, Inc. joint venture.
• Seek additional financing or strategic transactions to address liquidity needs and fund operations through December 31, 2025, and beyond.
• Address and remediate identified material weaknesses in internal controls and disclosure controls.

Key Dates

Recommendation

While Catheter Precision demonstrates impressive revenue growth and significant progress in product development, including a CE Mark and positive clinical data, these operational positives are heavily overshadowed by severe financial challenges. The company reported substantial net losses, has a critically low cash position of $838 thousand, and explicitly states it lacks sufficient liquidity to fund operations through December 31, 2025, without additional financing. Furthermore, the disclosure of ineffective internal controls for multiple periods raises serious concerns about financial reporting integrity and corporate governance. For a seasoned investor, the strong growth potential is undeniable, but the immediate and pressing financial risks, particularly the need for capital and internal control deficiencies, warrant a cautious 'hold' stance. Investors should monitor the company's ability to secure financing and remediate its internal control issues before considering a more aggressive position.

Keywords

Medical Device, Cardiac Electrophysiology, VIVO, LockeT, Ventricular Arrhythmia, Heart Failure, Ablation, SEC Filing, Earnings, Q2 2025, CE Mark, Clinical Data, Cardionomics, Kardionav